Articles from iORGANBIO

MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- iORGANBIO Inc. (“iORGANBIO”) today announced that it has received investment from Mitsui Chemicals, Inc. (Tokyo Stock Exchange: 4183; President & CEO: Satoshi Ichimura) (“Mitsui Chemicals”) through 321Catalyst™, Mitsui Chemicals’ corporate venture capital (CVC) fund.

iOrganBio, an innovator in intelligent cell manufacturing redefining how human cells are engineered and reliably produced at scale for research and therapy, including as New Approach Methodologies (NAMs) in alignment with FDA direction, today announced the appointment of Karol Jarzabek as Chief Operating Officer.

iOrganBio today announced its launch from stealth with $2 million in funding to transform how human cells are made. The round was led by First Star Ventures along with institutional investors IndieBio, Cape Fear BioCapital, 2ndF, Terasaki Institute, and Alix Ventures.